Skip to content

Clinical study on the curative effect of Erren Decoction and the basic research of the pharmacodynamic substances in treating the deficiency of spleen and kidney

Clinical study on the curative effect of Erren Decoction and the basic research of the pharmacodynamic substances in treating the deficiency of spleen and kidney

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077153
Enrollment
Unknown
Registered
2023-10-31
Start date
2023-11-01
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metrorrhagia and metrostaxis

Interventions

Observation group: Erren Decoction herbal formula granules
Control group: Erren Decoction

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
13 Years to 55 Years

Inclusion criteria

Inclusion criteria: (1) Age range: female patients aged 13 to 55 years. (2) Meet the diagnostic criteria for leaky diseases: menstrual cycle, menstrual period, menstrual volume disorder, manifested as a sudden large amount of sudden vaginal bleeding. (3) Consistent with TCM syndrome differentiation type: Main symptoms: ? abnormal menstrual blood burst down more than; ? Dark red or light red; ? Thin menstrual texture. Secondary symptoms: ? waist and knee weakness; ? Dizziness and tinnitus; ? insomnia and dreams; ? Fatigue; ? Pale or yellowish complexion. Tongue and pulse: the tongue is light and dark, the fur is thin and white, and the pulse is heavy and fine. The syndrome differentiation is spleen and kidney deficiency type, which must at least meet the requirements of the above main symptoms ?, and any one of the main symptoms ? and?, and any two of the secondary symptoms, combined with tongue and pulse. (4) Patients voluntarily participated in this study, signed written informed consent, and were willing to cooperate with follow-up.

Exclusion criteria

Exclusion criteria: (1) Organic lesions, such as genital benign and malignant tumors, such as uterine fibroids, uterine adenomyosis, cervical cancer and other causes of abnormal uterine bleeding. (2) Abnormal uterine bleeding caused by reproductive tract infection. (3) vulva, vagina and cervix bleeding. (4) Abnormal uterine bleeding caused by cardiovascular diseases, liver diseases, blood system diseases, etc. (5) Hemoglobin less than 80g/L. (6) Vaginal bleeding caused by pregnancy. (7) Within 10 days of taking drugs with hemostatic effect (as judged by the clinician), including traditional Chinese medicine, proprietary Chinese medicine and Western medicine.

Design outcomes

Primary

MeasureTime frame
Hemostasis rate within 7 days;

Secondary

MeasureTime frame
No bleeding duration;TCM syndrome integral;Global efficacy;Endometrial Thickness;

Countries

China

Contacts

Public ContactLing Zhu

Guangzhou University of Traditional Chinese Medicine

2275898821@qq.com+86 135 7057 8779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026